2-氨基-9-[4-羟基-5-(羟基甲基)四氢呋喃-2-基]-3H-嘌呤-6-硫酮 | 2133-81-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 2-氨基-9-[4-羟基-5-(羟基甲基)四氢呋喃-2-基]-3H-嘌呤-6-硫酮
• 英文名称: 2-amino-9-(2-deoxy-α-D-erythro-pentofuranosyl)purine-6(1H)-thione
• 英文别名: 9-(2-deoxy-α-D-erythro=pentofuranosyl)-6-thioguanine；2-amino-9-(α-D-erythro-2-deoxy-pentofuranosyl)-1,9-dihydro-purine-6-thione；(2R,3S,5S)-5-(2-amino-6-sulfanylpurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
• CAS: 2133-81-5
• 化学式: C₁₀H₁₃N₅O₃S
• 分子量: 283.311
• InChiKey: SCVJRXQHFJXZFZ-JKUQZMGJSA-N

物化性质

• 沸点：
  709.1±70.0 °C(Predicted)
• 密度：
  2.02±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  150
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-氨基-9-[4-羟基-5-(羟基甲基)四氢呋喃-2-基]-3H-嘌呤-6-硫酮 在 氢氧化钾 、 ammonium hydroxide 、 sodium hypochlorite 、 间氯过氧苯甲酸 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 生成 2-amino-9-(2-deoxy-α-D-erythro-pentofuranosyl)purine-6-sulfonamide
  参考文献：
  名称：

  Smee, Donald F.; Finch, Rick A.; Avery, Thomas L., Journal of Heterocyclic Chemistry, 1990, vol. 27, # 4, p. 909 - 918

  摘要：

  DOI：

文献信息

• Polynucleotide assay reagent and method
  申请人：ANTIVIRALS INC.

  公开号：EP0639582A2

  公开（公告）日：1995-02-22

  The invention provides a use of a morpholino subunit of the formula (I) where P is a purine or pyrimidine base-pairing moiety, and T is H or an N-protective group, for the production of a polymer capable of hydrogen-bonding to complementary bases in a polynucleotide, where in said polymer (i) the subunits are joined predominantly by substantially uncharged, achiral linkages, and (ii) each linkage joins the morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit.

  本发明提供了式 (I) 吗啉亚基的用途 其中 P 是嘌呤或嘧啶碱基配对分子，T 是 H 或 N 保护基团，用于生产能够与多核苷酸中的互补碱基发生氢键连接的聚合物，在所述聚合物中，(i) 亚基主要通过基本上不带电的非手性连接物连接，(ii) 每个连接物将一个亚基的吗啉基氮连接到相邻亚基的 5'外环碳上。
• Gene Therapy of Cancer: Activation of Nucleoside Prodrugs with<i>E. coli</i>Purine Nucleoside Phosphorylase
  作者：John A. Secrist、William B. Parker、Paula W. Allan、L. Lee Bennett、William R. Waud、Jackie W. Truss、Anita T. Fowler、John A. Montgomery、Steven E. Ealick、Alan H. Wells、G. Yancey Gillespie、V. K. Gadi、Eric J. Sorscher

  DOI：10.1080/15257779908041562

  日期：1999.4

  During the last few years, many gene therapy strategies have been developed for various disease targets. The development of anticancer gene therapy strategies to selectively generate cytotoxic nucleoside or nucleotide analogs is an attractive goal. One such approach involves the delivery of herpes simplex virus thymidine kinase followed by the acyclic nucleoside analog ganciclovir. We have developed another gene therapy methodology for the treatment of cancer that has several significant attributes. Specifically, our approach involves the delivery off. coli purine nucleoside phosphorylase, followed by treatment with a relatively non-toxic nucleoside prodrug that is cleaved by the enzyme to a toxic compound. This presentation describes the concept, details our search for suitable prodrugs, and summarizes the current biological data.
• REVANKAR, GANAPATH R.;HANNA, NAEEM B.;RAMASAMY, KANDASAMY;LARSON, STEVEN +, J. HETEROCYCL. CHEM., 27,(1990) N, C. 909-918
  作者：REVANKAR, GANAPATH R.、HANNA, NAEEM B.、RAMASAMY, KANDASAMY、LARSON, STEVEN +

  DOI：——

  日期：——
• STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS
  申请人：SUMMERTON, James

  公开号：EP0216860A1

  公开（公告）日：1987-04-08
• EP0216860A4
  申请人：——

  公开号：EP0216860A4

  公开（公告）日：1989-02-22